British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis.
Loading...
Embargo End Date
ICR Authors
Authors
Powell, N
Ibraheim, H
Raine, T
Speight, RA
Papa, S
Brain, O
Green, M
Samaan, MA
Spain, L
Yousaf, N
Hunter, N
Eldridge, L
Pavlidis, P
Irving, P
Hayee, B
Turajlic, S
Larkin, J
Lindsay, JO
Gore, M
Ibraheim, H
Raine, T
Speight, RA
Papa, S
Brain, O
Green, M
Samaan, MA
Spain, L
Yousaf, N
Hunter, N
Eldridge, L
Pavlidis, P
Irving, P
Hayee, B
Turajlic, S
Larkin, J
Lindsay, JO
Gore, M
Document Type
Journal Article
Date
2020-07-01
Date Accepted
2020-01-21
Abstract
Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction. Diarrhoea and gastrointestinal tract inflammation are common and sometimes serious side-effects of this type of therapy. Prompt recognition of gastrointestinal toxicity and, in many cases, rapid institution of anti-inflammatory or biologic therapy (or both) is required to reverse these complications. Management of organ-specific complications benefits from multidisciplinary input, including engagement with gastroenterologists for optimal management of immune checkpoint inhibitor-induced enterocolitis. In this British Society of Gastroenterology endorsed guidance document, we have developed a consensus framework for the investigation and management of immune checkpoint inhibitor-induced enterocolitis.
Citation
The Lancet Gastroenterology & Hepatology, 2020, 5 (7), pp. 679 - 697
Source Title
The Lancet Gastroenterology & Hepatology
Publisher
ELSEVIER INC
ISSN
2468-1253
eISSN
2468-1253
2468-1253
2468-1253